MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells

MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells

From: 485 USD
Catalog #
(Select a product)
Serum-free attachment substrate for human mesenchymal stem cells
Add to Wish List

Overview

Support the attachment and growth of human mesenchymal stem and progenitor cell (MSC) cultures in vitro with MesenCult™-SF Attachment Substrate. This serum-free cell culture substrate is optimized to enhance the expansion of human MSCs in vitro and support their enumeration using the colony-forming unit–fibroblast (CFU-F) assay.
Cell Type
Mesenchymal Stem and Progenitor Cells
Species
Human
Brand
MesenCult

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05424
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
05424
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus. C. Cantarelli et al. Frontiers in immunology 2019

Abstract

Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (TFH) and T follicular regulatory cells (TFR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer TFH and increased TFR. Together, the data support use of Prevnar vaccination in individuals with SLE.